Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: Cancer J Clin 2015; 65:5-29; PMID:25559415; http://dx.doi.org/10.1017/S0009840X14001668
   PubMed Web of Science ®Google Scholar
• Godley PA, Taylor M. Renal cell carcinoma. Curr Opin Oncol 2001; 13:199-203; PMID:11307065; http://dx.doi.org/10.1097/00001622-200105000-00012
   PubMed Web of Science ®Google Scholar
• Ather MH, Masood N, Siddiqui T. Current management of advanced and metastatic renal cell carcinoma. Urology J 2010; 7:1-9
   PubMed Web of Science ®Google Scholar
• Snow RM, Schellhammer PF. Spontaneous regression of metastatic renal cell carcinoma. Urology 1982; 20:177-81; PMID:7112827; http://dx.doi.org/10.1016/0090-4295(82)90356-9
   PubMed Web of Science ®Google Scholar
• McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer 2009; 115:2298-305; PMID:19402060; http://dx.doi.org/10.1002/cncr.24236
   PubMed Web of Science ®Google Scholar
• Dubrot J, Palazon A, Alfaro C, Azpilikueta A, Ochoa MC, Rouzaut A, Martinez-Forero I, Teijeira A, Berraondo P, Le Bon A, et al. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. Int J Cancer 2011; 128:105-18; PMID:20309938; http://dx.doi.org/10.1002/ijc.25333
   PubMed Web of Science ®Google Scholar
• Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011; 17:2619-27; PMID:21372217; http://dx.doi.org/10.1158/1078-0432.CCR-10-1114
   PubMed Web of Science ®Google Scholar
• Rocha FG, Chaves KC, Chammas R, Peron JP, Rizzo LV, Schor N, Bellini MH. Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice. Cancer Immunol Immunother 2010; 59:1357-65; PMID:20490489; http://dx.doi.org/10.1007/s00262-010-0865-6
   PubMed Web of Science ®Google Scholar
• Westwood JA, Darcy PK, Guru PM, Sharkey J, Pegram HJ, Amos SM, Smyth MJ, Kershaw MH. Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice. J Transl Med 2010; 8:42; PMID:20426873; http://dx.doi.org/10.1186/1479-5876-8-42
   PubMed Web of Science ®Google Scholar
• De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, Mazzoleni S, Moi D, Venneri MA, Indraccolo S, et al. Tumor-targeted interferon-α delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008; 14:299-311; PMID:18835032; http://dx.doi.org/10.1016/j.ccr.2008.09.004
   PubMed Web of Science ®Google Scholar
• Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17:2859-67; PMID:10561363
   PubMed Web of Science ®Google Scholar
• Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI, Rubinstein L, Louie A, Mier JW, Gucalp R, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993; 11:661-70; PMID:8478661
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584-90; PMID:19487381; http://dx.doi.org/10.1200/JCO.2008.20.1293
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-24; PMID:17215529; http://dx.doi.org/10.1056/NEJMoa065044
   PubMed Web of Science ®Google Scholar
• Larkin JM, Eisen T. Renal cell carcinoma and the use of sorafenib. Ther Clin Risk Manag 2006; 2:87-98; PMID:18360584
   PubMedGoogle Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/10.1038/nature10673
   PubMed Web of Science ®Google Scholar
• Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24:175-208; PMID:16551247; http://dx.doi.org/10.1146/annurev.immunol.24.021605.090733
   PubMed Web of Science ®Google Scholar
• Rohn TA, Reitz A, Paschen A, Nguyen XD, Schadendorf D, Vogt AB, Kropshofer H. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope. Cancer Res 2005; 65:10068-78; PMID:16267033; http://dx.doi.org/10.1158/0008-5472.CAN-05-1973
   PubMed Web of Science ®Google Scholar
• Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 2011; 30:150-82; PMID:21557641; http://dx.doi.org/10.3109/08830185.2011.572210
   PubMed Web of Science ®Google Scholar
• De Filippo M, Bozzetti F, Martora R, Zagaria R, Ferretti S, Macarini L, Brunese L, Rotondo A, Rossi C. Radiofrequency thermal ablation of renal tumors. Radiol Med 2014; 119:499-511; PMID:25024061; http://dx.doi.org/10.1007/s11547-014-0412-1
   PubMed Web of Science ®Google Scholar
• Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. Bmj 2014; 349:g4797; PMID:25385470; http://dx.doi.org/10.1136/bmj.g4797
   PubMed Web of Science ®Google Scholar
• Parashar B, Patro KC, Smith M, Arora S, Nori D, Wernicke AG. Role of radiation therapy for renal tumors. Semin Intervent Radiol 2014; 31:86-90; PMID:24596444; http://dx.doi.org/10.1055/s-0033-1363847
   PubMed Web of Science ®Google Scholar
• Griffith TS, Ferguson TA. Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells. Immunity 2011; 35:456-66; PMID:22035838; http://dx.doi.org/10.1016/j.immuni.2011.08.011
   PubMed Web of Science ®Google Scholar
• Ferguson TA, Stuart PM, Herndon JM, Griffith TS. Apoptosis, tolerance, and regulatory T cells–old wine, new wineskins. Immunol Rev 2003; 193:111-23; PMID:12752676; http://dx.doi.org/10.1034/j.1600-065X.2003.00042.x
   PubMed Web of Science ®Google Scholar
• Daste A, Grellety T, Gross-Goupil M, Ravaud A. Protein kinase inhibitors in renal cell carcinoma. Expert Opin Pharmacother 2014; 15:337-51; PMID:24328606; http://dx.doi.org/10.1517/14656566.2014.869210
   PubMed Web of Science ®Google Scholar
• Escudier B, Albiges L, Sonpavde G. Optimal management of metastatic renal cell carcinoma: current status. Drugs 2013; 73:427-38; PMID:23572408; http://dx.doi.org/10.1007/s40265-013-0043-1
   PubMed Web of Science ®Google Scholar
• Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82; PMID:8777713; http://dx.doi.org/10.1016/1074-7613(95)90057-8
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Herbst RS. To kill a tumor cell: The potential of proapoptotic receptor agonists. J Clin Invest 2008; 118:1979-90; PMID:18523647; http://dx.doi.org/10.1172/JCI34359
   PubMed Web of Science ®Google Scholar
• Holland PM. Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine Growth Factor Rev 2014; 25:185-93; PMID:24418173; http://dx.doi.org/10.1016/j.cytogfr.2013.12.009
   PubMed Web of Science ®Google Scholar
• Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ 2014; 21:1350-64; PMID:24948009; http://dx.doi.org/10.1038/cdd.2014.81
   PubMed Web of Science ®Google Scholar
• Griffith TS, Stokes B, Kucaba TA, Earel JK, Jr., VanOosten RL, Brincks EL, Norian LA. TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther 2009; 9:9-19; PMID:19275567; http://dx.doi.org/10.2174/156652309787354612
   PubMed Web of Science ®Google Scholar
• Holoch PA, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 2009; 625:63-72; PMID:19836385; http://dx.doi.org/10.1016/j.ejphar.2009.06.066
   PubMed Web of Science ®Google Scholar
• Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000; 165:2886-94; PMID:10946322; http://dx.doi.org/10.4049/jimmunol.165.5.2886
   PubMed Web of Science ®Google Scholar
• Griffith TS, Broghammer EL. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 2001; 4:257-66; PMID:11545617; http://dx.doi.org/10.1006/mthe.2001.0439
   PubMed Web of Science ®Google Scholar
• Norian LA, Kresowik TP, Rosevear HM, James BR, Rosean TR, Lightfoot AJ, Kucaba TA, Schwarz C, Weydert CJ, Henry MD, et al. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. PLoS One 2012; 7:e31085; PMID:22312440; http://dx.doi.org/10.1371/journal.pone.0031085
   PubMedGoogle Scholar
• VanOosten RL, Griffith TS. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res 2007; 67:11980-90; PMID:18089829; http://dx.doi.org/10.1158/0008-5472.CAN-07-1526
   PubMed Web of Science ®Google Scholar
• Wilson NS, Yang A, Yang B, Couto S, Stern H, Gogineni A, Pitti R, Marsters S, Weimer RM, Singh M, et al. Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. Cancer Cell 2012; 22:80-90; PMID:22789540; http://dx.doi.org/10.1016/j.ccr.2012.05.014
   PubMed Web of Science ®Google Scholar
• Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29:372-83; PMID:18799145; http://dx.doi.org/10.1016/j.immuni.2008.08.004
   PubMed Web of Science ®Google Scholar
• Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86-9; PMID:9510252; http://dx.doi.org/10.1038/32183
   PubMed Web of Science ®Google Scholar
• Bellone M, Iezzi G, Rovere P, Galati G, Ronchetti A, Protti MP, Davoust J, Rugarli C, Manfredi AA. Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol 1997; 159:5391-9; PMID:9548479
   PubMed Web of Science ®Google Scholar
• Blachere NE, Darnell RB, Albert ML. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol 2005; 3:e185; PMID:15839733; http://dx.doi.org/10.1371/journal.pbio.0030185
   PubMed Web of Science ®Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9:271-96; PMID:1910679; http://dx.doi.org/10.1146/annurev.iy.09.040191.001415
   PubMed Web of Science ®Google Scholar
• Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009; 9:353-63; PMID:19365408; http://dx.doi.org/10.1038/nri2545
   PubMed Web of Science ®Google Scholar
• Cowdery JS, Boerth NJ, Norian LA, Myung PS, Koretzky GA. Differential regulation of the IL-12 p40 promoter and of p40 secretion by CpG DNA and lipopolysaccharide. J Immunol 1999; 162:6770-5; PMID:10352297
   PubMed Web of Science ®Google Scholar
• Dalod M, Salazar-Mather TP, Malmgaard L, Lewis C, Asselin-Paturel C, Briere F, Trinchieri G, Biron CA. Interferon α/β and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J Exp Med 2002; 195:517-28; PMID:11854364; http://dx.doi.org/10.1084/jem.20011672
   PubMed Web of Science ®Google Scholar
• Gautier G, Humbert M, Deauvieau F, Scuiller M, Hiscott J, Bates EE, Trinchieri G, Caux C, Garrone P. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 2005; 201:1435-46; PMID:15851485; http://dx.doi.org/10.1084/jem.20041964
   PubMed Web of Science ®Google Scholar
• Hochrein H, Shortman K, Vremec D, Scott B, Hertzog P, O'Keeffe M. Differential production of IL-12, IFN-α, and IFN-gamma by mouse dendritic cell subsets. J Immunol 2001; 166:5448-55; PMID:11313382; http://dx.doi.org/10.4049/jimmunol.166.9.5448
   PubMed Web of Science ®Google Scholar
• James BR, Brincks EL, Kucaba TA, Boon L, Griffith TS. Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8a DC. Cancer Immunol Immunother 2014; 63:685-97; PMID:24711083; http://dx.doi.org/10.1007/s00262-014-1548-5
   PubMed Web of Science ®Google Scholar
• Liu RB, Engels B, Schreiber K, Ciszewski C, Schietinger A, Schreiber H, Jabri B. IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc Natl Acad Sci U S A 2013; 110:8158-63; PMID:23637340; http://dx.doi.org/10.1073/pnas.1301022110
   PubMed Web of Science ®Google Scholar
• Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998; 161:927-32; PMID:9670971
   PubMed Web of Science ®Google Scholar
• Gray RC, Kuchtey J, Harding CV. CpG-B ODNs potently induce low levels of IFN-alphabeta and induce IFN-alphabeta-dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs. J Leukoc Biol 2007; 81:1075-85; PMID:17227820; http://dx.doi.org/10.1189/jlb.1006606
   PubMed Web of Science ®Google Scholar
• Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M, Spada M, Belardelli F, Gabriele L, Schiavoni G. Type I IFNs control antigen retention and survival of CD8alpha(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol 2011; 186:5142-50; PMID:21441457; http://dx.doi.org/10.4049/jimmunol.1004163
   PubMed Web of Science ®Google Scholar
• Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, Wang G. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 2007; 178:1534-41; PMID:17237402; http://dx.doi.org/10.4049/jimmunol.178.3.1534
   PubMed Web of Science ®Google Scholar
• Figlin RA. A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma. Immunotherapy 2014; 6:261-8; PMID:24354908; http://dx.doi.org/10.2217/imt.13.168
   PubMed Web of Science ®Google Scholar
• Wang J, Liao L, Tan J. Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials. Immunotherapy 2012; 4:1031-42; PMID:23148755; http://dx.doi.org/10.2217/imt.12.107
   PubMed Web of Science ®Google Scholar
• Leonhartsberger N, Ramoner R, Falkensammer C, Rahm A, Gander H, Holtl L, Thurnher M. Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma. Cancer Immunol Immunother 2012; 61:1407-13; PMID:22278360; http://dx.doi.org/10.1007/s00262-012-1207-7
   PubMed Web of Science ®Google Scholar
• Draube A, Klein-Gonzalez N, Mattheus S, Brillant C, Hellmich M, Engert A, von Bergwelt-Baildon M. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 2011; 6:e18801; PMID:21533099; http://dx.doi.org/10.1371/journal.pone.0018801
   PubMed Web of Science ®Google Scholar
• Lion E, Smits EL, Berneman ZN, Van Tendeloo VF. NK cells: key to success of DC-based cancer vaccines? The oncologist 2012; 17:1256-70; PMID:22907975; http://dx.doi.org/10.1634/theoncologist.2011-0122
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Joniau S, Van Gool SW. Vaccine therapy in patients with renal cell carcinoma. Eur Urol 2009; 55:1333-42.
   Google Scholar
• Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623-33; PMID:16308572; http://dx.doi.org/10.1172/JCI25947
   PubMed Web of Science ®Google Scholar
• Poschke I, Mao Y, Adamson L, Salazar-Onfray F, Masucci G, Kiessling R. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother 2012; 61:827-38; PMID:22080405; http://dx.doi.org/10.1007/s00262-011-1143-y
   PubMed Web of Science ®Google Scholar
• Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 2011; 11:856-61; PMID:21315783; http://dx.doi.org/10.1016/j.intimp.2011.01.030
   PubMed Web of Science ®Google Scholar
• Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010; 70:3526-36; PMID:20406969; http://dx.doi.org/10.1158/0008-5472.CAN-09-3278
   PubMed Web of Science ®Google Scholar
• Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-57; PMID:19276286; http://dx.doi.org/10.1158/1078-0432.CCR-08-1332
   PubMed Web of Science ®Google Scholar
• Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol 2013; 3:49; PMID:23508517; http://dx.doi.org/10.3389/fonc.2013.00049
   PubMedGoogle Scholar
• Gulley JL, Madan RA, Schlom J. Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 2011; 18:e150-7; PMID:21655153; http://dx.doi.org/10.3747/co.v18i3.783
   PubMed Web of Science ®Google Scholar
• Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, Popescu F, Xiao Z. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 2006; 211:81-92; PMID:16824119; http://dx.doi.org/10.1111/j.0105-2896.2006.00382.x
   PubMed Web of Science ®Google Scholar
• Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004; 199:1607-18; PMID:15197224; http://dx.doi.org/10.1084/jem.20040317
   PubMed Web of Science ®Google Scholar
• Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003; 197:1141-51; PMID:12732656; http://dx.doi.org/10.1084/jem.20021910
   PubMed Web of Science ®Google Scholar
• Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005; 174:4465-9; PMID:15814665; http://dx.doi.org/10.4049/jimmunol.174.8.4465
   PubMed Web of Science ®Google Scholar
• Croft M. The TNF family in T cell differentiation and function–unanswered questions and future directions. Semin Immunol 2014; 26:183-90; PMID:24613728; http://dx.doi.org/10.1016/j.smim.2014.02.005
   PubMed Web of Science ®Google Scholar
• Ju SA, Cheon SH, Park SM, Tam NQ, Kim YM, An WG, Kim BS. Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice. Int J Cancer 2008; 122:2784-90; PMID:18360825; http://dx.doi.org/10.1002/ijc.23457
   PubMed Web of Science ®Google Scholar
• Sadun RE, Hsu WE, Zhang N, Nien YC, Bergfeld SA, Sabzevari H, Lutsiak ME, Khawli L, Hu P, Epstein AL. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J Immunother 2008; 31:235-45; PMID:18317364; http://dx.doi.org/10.1097/CJI.0b013e31816a88e0
   PubMed Web of Science ®Google Scholar
• Westwood JA, Potdevin Hunnam TC, Pegram HJ, Hicks RJ, Darcy PK, Kershaw MH. Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice. PLoS One 2014; 9:e95847; PMID:24788789; http://dx.doi.org/10.1371/journal.pone.0095847
   PubMed Web of Science ®Google Scholar
• Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004; 10:294-8; PMID:14981514; http://dx.doi.org/10.1038/nm999
   PubMed Web of Science ®Google Scholar
• Sayers TJ, Brooks AD, Seki N, Smyth MJ, Yagita H, Blazar BR, Malyguine AM. T cell lysis of murine renal cancer: multiple signaling pathways for cell death via Fas. J Leukoc Biol 2000; 68:81-6; PMID:10914493
   PubMed Web of Science ®Google Scholar
• Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 2002; 168:3484-92; PMID:11907109; http://dx.doi.org/10.4049/jimmunol.168.7.3484
   PubMed Web of Science ®Google Scholar
• Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003; 63:4095-100; PMID:12874012
   PubMed Web of Science ®Google Scholar
• Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ. How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 1998; 10:581-7; PMID:9794837; http://dx.doi.org/10.1016/S0952-7915(98)80227-6
   PubMed Web of Science ®Google Scholar
• Zhang B, Karrison T, Rowley DA, Schreiber H. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 2008; 118:1398-404; PMID:18317595; http://dx.doi.org/10.1172/JCI33522
   PubMed Web of Science ®Google Scholar
• Caligiuri MA. Human natural killer cells. Blood 2008; 112:461-9; PMID:18650461; http://dx.doi.org/10.1182/blood-2007-09-077438
   PubMed Web of Science ®Google Scholar
• Koopman LA, Kopcow HD, Rybalov B, Boyson JE, Orange JS, Schatz F, Masch R, Lockwood CJ, Schachter AD, Park PJ, et al. Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J Exp Med 2003; 198:1201-12; PMID:14568979; http://dx.doi.org/10.1084/jem.20030305
   PubMed Web of Science ®Google Scholar
• Vosshenrich CA, Garcia-Ojeda ME, Samson-Villeger SI, Pasqualetto V, Enault L, Richard-Le Goff O, Corcuff E, Guy-Grand D, Rocha B, Cumano A, et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol 2006; 7:1217-24; PMID:17013389; http://dx.doi.org/10.1038/ni1395
   PubMed Web of Science ®Google Scholar
• Ebert LM, Meuter S, Moser B. Homing and function of human skin gammadelta T cells and NK cells: relevance for tumor surveillance. J Immunol 2006; 176:4331-6; PMID:16547270; http://dx.doi.org/10.4049/jimmunol.176.7.4331
   PubMed Web of Science ®Google Scholar
• Peng H, Jiang X, Chen Y, Sojka DK, Wei H, Gao X, Sun R, Yokoyama WM, Tian Z. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J Clin Invest 2013; 123:1444-56; PMID:23524967; http://dx.doi.org/10.1172/JCI66381
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 1:41-9; PMID:11905813; http://dx.doi.org/10.1038/35095564
   PubMed Web of Science ®Google Scholar
• Miller JS. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol 2001; 29:1157-68; PMID:11602317; http://dx.doi.org/10.1016/S0301-472X(01)00696-8
   PubMed Web of Science ®Google Scholar
• Yokoyama WM, Kim S, French AR. The dynamic life of natural killer cells. Annu Rev Immunol 2004; 22:405-29; PMID:15032583; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104711
   PubMed Web of Science ®Google Scholar
• Lash GE, Schiessl B, Kirkley M, Innes BA, Cooper A, Searle RF, Robson SC, Bulmer JN. Expression of angiogenic growth factors by uterine natural killer cells during early pregnancy. J Leukoc Biol 2006; 80:572-80; PMID:16816146; http://dx.doi.org/10.1189/jlb.0406250
   PubMed Web of Science ®Google Scholar
• Li XF, Charnock-Jones DS, Zhang E, Hiby S, Malik S, Day K, Licence D, Bowen JM, Gardner L, King A, et al. Angiogenic growth factor messenger ribonucleic acids in uterine natural killer cells. J Clin Endocrinol Metab 2001; 86:1823-34; PMID:11297624
   PubMed Web of Science ®Google Scholar
• Santoni A, Carlino C, Gismondi A. Uterine NK cell development, migration and function. Reprod Biomed Online 2008; 16:202-10; PMID:18284874; http://dx.doi.org/10.1016/S1472-6483(10)60575-5
   PubMed Web of Science ®Google Scholar
• Hatta K, Carter AL, Chen Z, Leno-Duran E, Ruiz-Ruiz C, Olivares EG, Tse MY, Pang SC, Croy BA. Expression of the vasoactive proteins AT1, AT2, and ANP by pregnancy-induced mouse uterine natural killer cells. Reprod Sci 2011; 18:383-90; PMID:20959647; http://dx.doi.org/10.1177/1933719110385136
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen Z, Smith GN, Croy BA. Natural killer cell-triggered vascular transformation: maternal care before birth? Cell Mol Immunol 2011; 8:1-11; PMID:20711229; http://dx.doi.org/10.1038/cmi.2010.38
   PubMed Web of Science ®Google Scholar
• Quenby S, Nik H, Innes B, Lash G, Turner M, Drury J, Bulmer J. Uterine natural killer cells and angiogenesis in recurrent reproductive failure. Hum Reprod 2009; 24:45-54; PMID:18835875; http://dx.doi.org/10.1093/humrep/den348
   PubMed Web of Science ®Google Scholar
• Ayach BB, Yoshimitsu M, Dawood F, Sun M, Arab S, Chen M, Higuchi K, Siatskas C, Lee P, Lim H, et al. Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. Proc Natl Acad Sci U S A 2006; 103:2304-9; PMID:16467148; http://dx.doi.org/10.1073/pnas.0510997103
   PubMed Web of Science ®Google Scholar
• Bouchentouf M, Forner KA, Cuerquis J, Michaud V, Zheng J, Paradis P, Schiffrin EL, Galipeau J. Induction of cardiac angiogenesis requires killer cell lectin-like receptor 1 and alpha4beta7 integrin expression by NK cells. J Immunol 2010; 185:7014-25; PMID:20971926; http://dx.doi.org/10.4049/jimmunol.1001888
   PubMed Web of Science ®Google Scholar
• Keskin DB, Allan DS, Rybalov B, Andzelm MM, Stern JN, Kopcow HD, Koopman LA, Strominger JL. TGFbeta promotes conversion of CD16+ peripheral blood NK cells into CD16- NK cells with similarities to decidual NK cells. Proc Natl Acad Sci U S A 2007; 104:3378-83; PMID:17360654; http://dx.doi.org/10.1073/pnas.0611098104
   PubMed Web of Science ®Google Scholar
• Jones RL, Stoikos C, Findlay JK, Salamonsen LA. TGF-β superfamily expression and actions in the endometrium and placenta. Reproduction 2006; 132:217-32; PMID:16885531; http://dx.doi.org/10.1530/rep.1.01076
   PubMed Web of Science ®Google Scholar
• Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, Häntschel M, Brugger W, Schröder S, Horger MS, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006; 66:5910-8; PMID:16740731; http://dx.doi.org/10.1158/0008-5472.CAN-05-3905
   PubMed Web of Science ®Google Scholar
• Cozar JM, Canton J, Tallada M, Concha A, Cabrera T, Garrido F, Ruiz-Cabello Osuna F. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol Immunother 2005; 54:858-66; PMID:15887015; http://dx.doi.org/10.1007/s00262-004-0646-1
   PubMed Web of Science ®Google Scholar
• Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006; 24:1997-2005; PMID:16648500; http://dx.doi.org/10.1200/JCO.2005.03.9594
   PubMed Web of Science ®Google Scholar
• Kowalczyk D, Skorupski W, Kwias Z, Nowak J. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. Br J Urol 1997; 80:543-7; PMID:9352689; http://dx.doi.org/10.1046/j.1464-410X.1997.00408.x
   PubMedGoogle Scholar
• Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Grone EF, Hohenfellner M, Haferkamp A, Pohla H, Schendel DJ, et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 2006; 12:718-25; PMID:16467081; http://dx.doi.org/10.1158/1078-0432.CCR-05-0857
   PubMed Web of Science ®Google Scholar
• Donskov F, Bennedsgaard KM, Von Der Maase H, Marcussen N, Fisker R, Jensen JJ, Naredi P, Hokland M. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br J Cancer 2002; 87:194-201; PMID:12107842; http://dx.doi.org/10.1038/sj.bjc.6600437
   PubMed Web of Science ®Google Scholar
• Toliou T, Stravoravdi P, Polyzonis M, Vakalikos J. Natural killer cell activation after interferon administration in patients with metastatic renal cell carcinoma: an ultrastructural and immunohistochemical study. Eur Urol 1996; 29:252-6; PMID:8647158
   PubMed Web of Science ®Google Scholar
• Schleypen JS, Von Geldern M, Weiss EH, Kotzias N, Rohrmann K, Schendel DJ, Falk CS, Pohla H. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer 2003; 106:905-12; PMID:12918068; http://dx.doi.org/10.1002/ijc.11321
   PubMed Web of Science ®Google Scholar
• Frankenberger B, Noessner E, Schendel DJ. Immune suppression in renal cell carcinoma. Semin Cancer Biol 2007; 17:330-43; PMID:17656104; http://dx.doi.org/10.1016/j.semcancer.2007.06.004
   PubMed Web of Science ®Google Scholar
• Gati A, Da Rocha S, Guerra N, Escudier B, Moretta A, Chouaib S, Angevin E, Caignard A. Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients. Int J Cancer 2004; 109:393-401; PMID:14961578; http://dx.doi.org/10.1002/ijc.11730
   PubMed Web of Science ®Google Scholar
• Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995; 76:824-32; PMID:8625186; http://dx.doi.org/10.1002/1097-0142(19950901)76:5%3c824::AID-CNCR2820760517%3e3.0.CO;2-N
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313:1485-92; PMID:3903508; http://dx.doi.org/10.1056/NEJM198512053132327
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271:907-13; PMID:8120958; http://dx.doi.org/10.1001/jama.1994.03510360033032
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-7; PMID:15632206; http://dx.doi.org/10.1182/blood-2004-07-2974
   PubMed Web of Science ®Google Scholar
• Klingemann HG. Natural killer cell-based immunotherapeutic strategies. Cytotherapy 2005; 7:16-22; PMID:16040380; http://dx.doi.org/10.1016/S1465-3249(05)70785-4
   PubMed Web of Science ®Google Scholar
• Tam YK, Martinson JA, Doligosa K, Klingemann HG. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy 2003; 5:259-72; PMID:12850795; http://dx.doi.org/10.1080/14653240310001523
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90:51-81; PMID:16730261; http://dx.doi.org/10.1016/S0065-2776(06)90002-9
   PubMed Web of Science ®Google Scholar
• Algarra I, Cabrera T, Garrido F. The HLA crossroad in tumor immunology. Hum Immunol 2000; 61:65-73; PMID:10658979; http://dx.doi.org/10.1016/S0198-8859(99)00156-1
   PubMed Web of Science ®Google Scholar
• Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014; 2:3; PMID:24829760; http://dx.doi.org/10.1186/2051-1426-2-3
   PubMedGoogle Scholar
• Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5:200ra116; PMID:23986400; http://dx.doi.org/10.1126/scitranslmed.3006504
   PubMed Web of Science ®Google Scholar
• Godwin JL, Zibelman M, Plimack ER, Geynisman DM. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discov Med 2014; 18:341-50; PMID:25549705
   PubMedGoogle Scholar
• Xu KY, Wu S. Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma. Biomark Res 2015; 3:5; PMID:25734007; http://dx.doi.org/10.1186/s40364-015-0030-7
   PubMed Web of Science ®Google Scholar
• Sonnenfeld A. Leukamische reaktiones bei carcinoma. Zeitschrift f Klin Med 1929; 111:108
   Google Scholar
• Duwe AK, Singhal SK. The immunoregulatory role of bone marrow. I. Suppression of the induction of antibody responses to T-dependent and T-independent antigens by cells in the bone marrow. Cellular immunology 1979; 43:362-71; PMID:314345; http://dx.doi.org/10.1016/0008-8749(79)90180-1
   PubMed Web of Science ®Google Scholar
• Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16:53-65; PMID:16168663; http://dx.doi.org/10.1016/j.semcancer.2005.07.005
   PubMed Web of Science ®Google Scholar
• Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007; 67:10019-26; PMID:17942936; http://dx.doi.org/10.1158/0008-5472.CAN-07-2354
   PubMed Web of Science ®Google Scholar
• Eruslanov E, Daurkin I, Ortiz J, Vieweg J, Kusmartsev S. Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE(2) catabolism in myeloid cells. J Leukoc Biol 2010; 88:839-48; PMID:20587738; http://dx.doi.org/10.1189/jlb.1209821
   PubMed Web of Science ®Google Scholar
• Haverkamp JM, Crist SA, Elzey BD, Cimen C, Ratliff TL. In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol 2011; 41:749-59; PMID:21287554; http://dx.doi.org/10.1002/eji.201041069
   PubMed Web of Science ®Google Scholar
• Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111:4233-44; PMID:18272812; http://dx.doi.org/10.1182/blood-2007-07-099226
   PubMed Web of Science ®Google Scholar
• Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, Kalinski P. PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest 2012; 41:635-57; PMID:23017139; http://dx.doi.org/10.3109/08820139.2012.695417
   PubMed Web of Science ®Google Scholar
• Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205:2235-49; PMID:18809714; http://dx.doi.org/10.1084/jem.20080132
   PubMed Web of Science ®Google Scholar
• Geary SM, Lemke CD, Lubaroff DM, Salem AK. The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system. PLoS One 2013; 8:e67904; PMID:23840786; http://dx.doi.org/10.1371/journal.pone.0067904
   PubMed Web of Science ®Google Scholar
• Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008; 181:4666-75; PMID:18802069; http://dx.doi.org/10.4049/jimmunol.181.7.4666
   PubMed Web of Science ®Google Scholar
• Mao Y, Poschke I, Wennerberg E, Pico de Coana Y, Egyhazi Brage S, Schultz I, Hansson J, Masucci G, Lundqvist A, Kiessling R. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res 2013; 73:3877-87; PMID:23633486; http://dx.doi.org/10.1158/0008-5472.CAN-12-4115
   PubMed Web of Science ®Google Scholar
• Serafini P. Editorial: PGE2-producing MDSC: a role in tumor progression? J Leukoc Biol 2010; 88:827-9; PMID:21041513; http://dx.doi.org/10.1189/jlb.0510303
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Rev Immunol 2009; 9:162-74; http://dx.doi.org/10.1038/nri2506
   PubMed Web of Science ®Google Scholar
• Fleming TJ, Fleming ML, Malek TR. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol 1993; 151:2399-408; PMID:8360469
   PubMed Web of Science ®Google Scholar
• Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN, Vosshenrich CA. IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 2010; 40:3347-57; PMID:21110318; http://dx.doi.org/10.1002/eji.201041037
   PubMed Web of Science ®Google Scholar
• Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181:5791-802; PMID:18832739; http://dx.doi.org/10.4049/jimmunol.181.8.5791
   PubMed Web of Science ®Google Scholar
• Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182:5693-701; PMID:19380816; http://dx.doi.org/10.4049/jimmunol.0900092
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008; 222:180-91; PMID:18364002; http://dx.doi.org/10.1111/j.1600-065X.2008.00608.x
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor EM, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004; 64:5839-49; PMID:15313928; http://dx.doi.org/10.1158/0008-5472.CAN-04-0465
   PubMed Web of Science ®Google Scholar
• Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65:3044-8; PMID:15833831
   PubMed Web of Science ®Google Scholar
• Raber PL, Thevenot P, Sierra R, Wyczechowska D, Halle D, Ramirez ME, Ochoa AC, Fletcher M, Velasco C, Wilk A, et al. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer 2014; 134:2853-64; PMID:24259296; http://dx.doi.org/10.1002/ijc.28622
   PubMed Web of Science ®Google Scholar
• Qu X, Felder MA, Perez Horta Z, Sondel PM, Rakhmilevich AL. Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. Int Immunopharmacol 2013; 17:1141-7; PMID:24201083; http://dx.doi.org/10.1016/j.intimp.2013.10.019
   PubMed Web of Science ®Google Scholar
• Macleod LC, Hotaling JM, Wright JL, Davenport MT, Gore JL, Harper J, White E. Risk factors for renal cell carcinoma in the VITAL study. J Urol 2013; 190:1657-61; PMID:23665301; http://dx.doi.org/10.1016/j.juro.2013.04.130
   PubMed Web of Science ®Google Scholar
• Hjartaker A, Langseth H, Weiderpass E. Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol 2008; 630:72-93; PMID:18637486; http://dx.doi.org/10.1007/978-0-387-78818-0_6
   PubMed Web of Science ®Google Scholar
• Laber DA. Risk factors, classification, and staging of renal cell cancer. Med Oncol 2006; 23:443-54; PMID:17303902; http://dx.doi.org/10.1385/MO:23:4:443
   PubMed Web of Science ®Google Scholar
• James BR, Anderson KG, Brincks EL, Kucaba TA, Norian LA, Masopust D, Griffith TS. CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. Cancer Immunol Immunother 2014; 63:1213-27; PMID:25143233; http://dx.doi.org/10.1007/s00262-014-1598-8
   PubMed Web of Science ®Google Scholar
• James BR, Tomanek-Chalkley A, Askeland EJ, Kucaba T, Griffith TS, Norian LA. Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth. J Immunol 2012; 189:1311-21; PMID:22745381; http://dx.doi.org/10.4049/jimmunol.1100587
   PubMed Web of Science ®Google Scholar